ValiRx plc

ValiRx plc, through its subsidiaries, develops oncology therapeutics and companion diagnostics in the United Kingdom. Its pipeline includes VAL401, a reformulation of the anti-psychotic drug risperidone that completed a Phase II trial for end-stage non-small cell lung cancer; VAL201, a short peptide that completed a Phase I/II trial for prostate cancer; and VAL301, a peptide in pre-clinical development for endometriosis. The company is also developing BC201, a combination of the peptide ingredient of VAL201/VAL301 with complementary active components for SARS-CoV2 infection, and CLX001, a peptide in a nanoparticle formulation for triple negative breast cancer. Founded in 2006, ValiRx is based in London, the United Kingdom.